Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert W Postma is Director at Alaunos Therapeutics. OQRO lists 5 transactions filed with the SEC under this name, the latest on Oct 8, 2026, each linked to the official Form 4.
Director
Disclosures on record
5
Companies involved
1
As of the latest filing on , Robert W Postma reported holding 80,438 shares of Alaunos Therapeutics (TCRT), worth about $128K at the last close of $2 (Nov 19, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Alaunos Therapeutics TCRT | 80,438 | 80K direct | $2 | $128K | Oct 6, 2026 |
Is this Robert W Postma’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Alaunos TherapeuticsTCRT
5 disclosures · Nov 2025 – Oct 2026
Oct 6, 202622Kdisclosed Oct 8
DetailsOfficial recordJul 23, 20268,463disclosed Jul 27
DetailsOfficial recordApr 29, 20266,274disclosed May 1
DetailsOfficial recordJan 12, 20265,622disclosed Jan 15
DetailsOfficial recordNov 21, 20255,142disclosed Nov 27
DetailsOfficial recordRobert W Postma bought shares on the open market in 2021 and 2022, and has not bought since 2022.
Robert W Postma reported 3 open-market purchases and 0 sales since 2021; purchases in 2 different years, most recently 2022.
| Year | Bought | Sold |
|---|---|---|
| 2022 | $488K1×1 trade | — |
| 2021 | $130K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Robert W Postma reported 3 open-market purchases and 0 sales here, 2021 to 2022.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
On the latest SEC Form 4, dated Oct 6, 2026, Robert W Postma reported holding 80,438 shares of Alaunos Therapeutics (TCRT). At the last close of $2 on Nov 19, 2026, that is about $128K. This is the stake disclosed in filings, not a net worth.
No public filing gives Robert W Postma's net worth. What SEC Form 4 shows is the stock stake: 80,438 shares of Alaunos Therapeutics (TCRT), about $128K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Robert W Postma bought shares on the open market in 2021 and 2022, and has not bought since 2022.
In SEC filings since 2021: the latest open-market purchase is from 2022; no open-market sale is on record.
Alaunos Therapeutics (TCRT), from 2021 to 2022: 3 purchases and 0 sales.